stockrow
Friday 6 November 2026
Export NVST’s income statement to Excel — free account
Envista Holdings Corporation
NVST Healthcare Medical Instruments & Supplies
Envista Holdings Corporation’s revenue for fiscal 2025 (year ended December 2025) was $2.7 billion, up 8.32% from fiscal 2024.
- Revenue
- +3.22%
- EPS
- +1,855.6%
- Free cash flow
- −6.48%
- Total debt
- −1.13%
Quarter to September 2026, against a year earlier
24.98
2.21
−8.13%
Follow NVST
Alert me
| Sep '26 From the 10-Q filed 4 Nov | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
5.97 | 44.66 | 60.40 | 77.54 |
+8 more quarters Free account |
P/S ratio |
1.31 | 1.49 | 1.48 | 1.34 | |
P/FCF ratio |
15.43 | 17.13 | 18.87 | 15.80 | |
P/Operating CF |
48.45 | 35.79 | (1,260.04) | 33.77 | |
P/B ratio |
1.22 | 1.39 | 1.35 | 1.17 | |
Price to Tangible BV |
24.85 | 38.96 | 47.96 | 30.17 | |
EV/Sales |
1.45 | 1.64 | 1.65 | 1.47 | |
EV/EBITDA |
9.70 | 10.94 | 11.68 | 10.78 | |
EV/Operating CF |
13.79 | 15.51 | 17.02 | 14.51 | |
EV/FCF |
17.01 | 18.85 | 21.02 | 17.32 | |
Quick Ratio |
1.97 | 1.94 | 1.93 | 1.93 | |
Current Ratio |
2.45 | 2.43 | 2.44 | 2.38 | |
Net Debt/EBITDA |
0.00 | 2.62 | 3.50 | 2.11 | |
Debt/Assets |
25.47% | 25.66% | 25.80% | 25.50% | |
Debt/Equity |
0.46 | 0.47 | 0.47 | 0.47 | |
Asset Turnover |
0.51 | 0.51 | 0.51 | 0.49 | |
Operating CF/Net income |
0.15 | 2.22 | (0.09) | 3.28 | |
Capex/Depreciation |
0.00 | (0.37) | (0.32) | (0.42) | |
Interest Coverage |
66.05 | 9.23 | 8.45 | 7.12 | |
Research and Development Expense of Revenue |
4.24% | 4.16% | 4.25% | 4.28% | |
Selling, General and Administrative Expense of Revenue |
41.10% | 40.56% | 42.18% | 40.66% | |
Intangible Assets out of Total Assets |
0.52 | 0.53 | 0.54 | 0.53 | |
Share Based Compensation of Revenue |
1.42% | 1.30% | 1.45% | 1.39% | |
Graham Net Nets |
(0.14) | (0.13) | (0.14) | (0.15) | |
Graham Number |
41.21 | 15.88 | 13.33 | 10.79 | |
Earnings Yield |
16.74% | 2.24% | 1.66% | 1.29% | |
Free Cash Flow Yield |
6.48% | 5.84% | 5.30% | 6.33% | |
Revenue per Share |
4.30 | 4.51 | 4.30 | 4.47 | |
Operating CF per Share |
0.48 | 0.74 | (0.02) | 0.64 | |
Capex per Share |
(0.09) | (0.09) | (0.08) | (0.10) | |
Free Cash Flow per Share |
0.39 | 0.65 | (0.10) | 0.55 | |
Cash per Share |
7.21 | 6.95 | 6.61 | 7.21 | |
Shareholders Equity per Share |
19.21 | 19.00 | 18.79 | 18.49 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
19.21 | 19.00 | 18.79 | 18.49 | |
Free Cash Flow |
63.50 | 105.10 | (15.70) | 91.70 | |
Working Capital |
1,185.50 | 1,150.70 | 1,132.50 | 1,174.00 | |
Capital Expenditures |
(14.40) | (14.10) | (12.40) | (16.30) | |
Net Current Asset Value |
(520.60) | (562.80) | (579.40) | (546.10) | |
EV/EBIT |
5.69 | 17.15 | 19.33 | 18.51 | |
Capex to Sales |
0.02 | 0.02 | 0.02 | 0.02 | |
Price to Operating Income |
5.16 | 15.59 | 17.35 | 16.88 | |
| Other line items | |||||
Average Receivables |
427.20 | 429.85 | 414.85 | 396.30 | |
Average Payables |
163.90 | 181.00 | 166.75 | 183.10 | |
Average Inventory |
288.00 | 286.40 | 280.80 | 264.55 | |
Average Assets |
5,626.75 | 5,630.75 | 5,522.20 | 5,514.75 | |
Average Common Equity |
3,088.40 | 3,107.65 | 3,057.80 | 3,020.55 |
Columns are period end dates · fundamentals updated 4 Nov 2026